Ivermectin
Ivermectin, Sklice, Soolantra, Stromectol (ivermectin) is an unknown pharmaceutical. Ivermectin was first approved as Stromectol on 1996-11-22. It is used to treat ascariasis, elephantiasis, enterobiasis, lice infestations, and mansonelliasis amongst others in the USA. It is known to target P2X purinoceptor 4, neuronal acetylcholine receptor subunit alpha-7, and P2X purinoceptor 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Sklice, Soolantra, Stromectol (generic drugs available since 2014-10-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ivermectin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SKLICE | Arbor Pharmaceuticals | N-202736 OTC | 2012-02-07 | 1 products, RLD, RS |
| SOOLANTRA | Galderma | N-206255 RX | 2014-12-19 | 1 products, RLD, RS |
| STROMECTOL | Merck Sharp & Dohme | N-050742 RX | 1998-10-08 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| brimonidine tartrate 0.25% / ivermectin 1% / metronidazole 1% / niacinamide 4% | unapproved drug other | 2019-05-15 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ivermectin, Soolantra, Galderma Labs Lp | |||
| 9089587 | 2034-03-13 | U-1631 | |
| 9233117 | 2034-03-13 | U-1631 | |
| 9233118 | 2034-03-13 | U-1631 | |
| 9782425 | 2034-03-13 | U-1631 | |
| 10206939 | 2034-03-13 | U-1631 | |
| 7550440 | 2024-04-22 | DP | U-1631 |
| 8080530 | 2024-04-22 | DP | U-1631 |
| 8093219 | 2024-04-22 | DP | U-1631 |
| 8415311 | 2024-04-22 | DP | U-1631 |
| 8470788 | 2024-04-22 | DP | U-1631 |
| 8815816 | 2024-04-22 | DP | U-1631 |
| 11033565 | 2024-04-22 | DP | |
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX22: Ivermectin
P: Antiparasitic products, insecticides and repellents
— P02: Anthelmintics
— P02C: Antinematodal agents
— P02CF: Avermectines
— P02CF01: Ivermectin
HCPCS
No data
Clinical
Clinical Trials
229 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 9 | 33 | 30 | 7 | 16 | 78 |
| Filarial elephantiasis | D004605 | EFO_0007272 | B74.0 | — | 4 | 4 | 4 | 8 | 19 |
| Scabies | D012532 | — | B86 | 1 | 3 | 6 | 2 | 4 | 16 |
| Onchocerciasis | D009855 | EFO_0007402 | B73 | — | 5 | 5 | 1 | 5 | 16 |
| Rosacea | D012393 | — | L71 | 2 | 3 | 6 | 2 | — | 12 |
| Malaria | D008288 | EFO_0001068 | B54 | 2 | 3 | 6 | 1 | 1 | 11 |
| Healthy volunteers/patients | — | — | — | 7 | 1 | — | 1 | — | 8 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 2 | 3 | 1 | 1 | 5 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | 2 | 2 | 4 |
| Trachoma | D014141 | — | A71 | — | — | 1 | 2 | — | 3 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 2 | 5 | 1 | — | 1 | 8 |
| Trichuriasis | D014257 | EFO_0007524 | B79 | — | 4 | 4 | — | 1 | 7 |
| Pediculus | D010374 | — | — | 1 | 1 | 5 | — | — | 7 |
| Strongyloidiasis | D013322 | EFO_0007501 | B78 | — | — | 5 | — | 1 | 6 |
| Infections | D007239 | EFO_0000544 | — | — | 3 | 4 | — | 1 | 6 |
| Lice infestations | D010373 | — | B85.2 | 1 | — | 1 | — | 2 | 4 |
| Ascariasis | D001196 | EFO_0007154 | B77 | — | 2 | 2 | — | 1 | 4 |
| Hookworm infections | D006725 | EFO_0007314 | B76 | — | 2 | 2 | — | 1 | 4 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | 1 | — | — | 1 |
| Dengue | D003715 | — | A90 | — | 1 | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | 2 | 3 | — | — | 1 | 4 |
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | 1 | 1 | — | — | 2 | 4 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 2 | 2 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | 1 | 2 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | 1 | 1 | — | — | 1 | 2 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
| Ocular onchocerciasis | D015827 | EFO_0007398 | B73 | — | 1 | — | — | — | 1 |
| Severe dengue | D019595 | — | A91 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | — | 4 | 4 |
| Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Dna sequence analysis | D017422 | — | — | — | — | — | — | 1 | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | — | 1 | 1 |
| Smoking | D012907 | EFO_0004318 | — | — | — | — | — | 1 | 1 |
| Radiation exposure | D000069079 | — | — | — | — | — | — | 1 | 1 |
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ivermectin |
| INN | ivermectin |
| Description | Ivermectin is an antiparasitic drug. After its discovery in 1975, its first uses were in veterinary medicine to prevent and treat heartworm and acariasis. Approved for human use in 1987, it is used to treat infestations including head lice, scabies, river blindness (onchocerciasis), strongyloidiasis, trichuriasis, ascariasis and lymphatic filariasis. It works through many mechanisms to kill the targeted parasites, and can be taken by mouth, or applied to the skin for external infestations. It belongs to the avermectin family of medications.
|
| Classification | Small molecule |
| Drug class | antiparasitics (ivermectin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 70288-86-7 |
| RxCUI | 6069 |
| ChEMBL ID | CHEMBL1200633 |
| ChEBI ID | — |
| PubChem CID | 9812710 |
| DrugBank | DB00602 |
| UNII ID | 8883YP2R6D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
P2RX4
P2RX4
CHRNA7
CHRNA7
P2RX7
P2RX7
Organism
Homo sapiens
Gene name
P2RX4
Gene synonyms
NCBI Gene ID
Protein name
P2X purinoceptor 4
Protein synonyms
ATP receptor, ATP-gated cation channel protein, P2X receptor, subunit 4, Purinergic receptor, purinergic receptor P2X, ligand gated ion channel, 4, purinergic receptor P2X4, purinoceptor P2X4
Uniprot ID
Mouse ortholog
P2rx4 (18438)
P2X purinoceptor 4 (Q9JJX6)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Ivermectin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,428 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,799 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use